A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma
Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out whether IMPRINT in combination with pembrolizumab is
a safe treatment for people with malignant pleural mesothelioma (MPM).The highest dose of
IMPRINT that causes few or mild side effects when given in combination with pembrolizumab
will be found. Once the highest safe dose of IMPRINT is found, it will be tested in
combination with pembrolizumab in future participants to see whether the combination may be
an effective treatment for MPM.